In8bio Inc Stock Performance
| INAB Stock | USD 2.30 0.13 5.99% |
The company owns a Beta (Systematic Risk) of 1.0, which attests to possible diversification benefits within a given portfolio. In8bio returns are very sensitive to returns on the market. As the market goes up or down, In8bio is expected to follow. At this point, In8bio Inc has a negative expected return of -1.12%. Please make sure to check out In8bio's mean deviation, jensen alpha, potential upside, as well as the relationship between the standard deviation and treynor ratio , to decide if In8bio Inc performance from the past will be repeated at future time.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days In8bio Inc has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in August 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return (1.36) | Year To Date Return (74.20) | Ten Year Return (99.28) | All Time Return (99.28) |
Last Split Factor 1:30 | Last Split Date 2025-06-06 |
1 | Disposition of 81967 shares by Brandt Peter C. of In8bio at 1.5 subject to Rule 16b-3 | 04/25/2025 |
2 | Disposition of 81967 shares by Brandt Peter C. of In8bio at 0.1844 subject to Rule 16b-3 | 04/30/2025 |
3 | Disposition of 81967 shares by William Ho of In8bio at 0.45 subject to Rule 16b-3 | 05/01/2025 |
4 | Disposition of 574241 shares by Kreis Leslie W. of In8bio at 1.5 subject to Rule 16b-3 | 05/02/2025 |
5 | Acquisition by Roemer Alan S. of 63150 shares of In8bio at 0.17 subject to Rule 16b-3 | 05/08/2025 |
6 | IN8bio Showcases Advanced Cell Therapy Manufacturing Breakthroughs INAB Stock News | 05/12/2025 |
7 | IN8bio Presents Preclinical Data Highlighting Potential of INB-619 T Cell Engager for Autoimmune Disease at ASGCT 2025 | 05/14/2025 |
8 | Disposition of 20492 shares by Mccall Patrick of In8bio at 1.5 subject to Rule 16b-3 | 05/16/2025 |
9 | Acquisition by Greenwood Luba of 63150 shares of In8bio at 0.17 subject to Rule 16b-3 | 05/23/2025 |
10 | IN8bio Reports Promising Long-Term Data from INB-200 Clinical Trial INAB Stock News | 06/02/2025 |
11 | INAB Stock Trading Halted Pending Major Announcement INAB Stock News - GuruFocus | 06/05/2025 |
12 | INABs INB-200 Achieves Key Milestone in Phase 1 Trial for GBM INAB Stock News | 06/09/2025 |
13 | IN8bio Upgraded at Wall Street Zen | 06/10/2025 |
14 | Disposition of 102459 shares by Roemer Alan S. of In8bio at 0.1844 subject to Rule 16b-3 | 06/17/2025 |
15 | IN8bio regains compliance with Nasdaq minimum bid price requirement - Investing.com | 06/30/2025 |
| Begin Period Cash Flow | 21.5 M | |
| Total Cashflows From Investing Activities | -187 K |
In8bio Relative Risk vs. Return Landscape
If you would invest 525.00 in In8bio Inc on April 22, 2025 and sell it today you would lose (295.00) from holding In8bio Inc or give up 56.19% of portfolio value over 90 days. In8bio Inc is currently does not generate positive expected returns and assumes 5.9224% risk (volatility on return distribution) over the 90 days horizon. In different words, 53% of stocks are less volatile than In8bio, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
In8bio Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for In8bio's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as In8bio Inc, and traders can use it to determine the average amount a In8bio's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1891
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | INAB |
Estimated Market Risk
| 5.92 actual daily | 53 53% of assets are less volatile |
Expected Return
| -1.12 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.19 actual daily | 0 Most of other assets perform better |
Based on monthly moving average In8bio is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of In8bio by adding In8bio to a well-diversified portfolio.
In8bio Fundamentals Growth
In8bio Stock prices reflect investors' perceptions of the future prospects and financial health of In8bio, and In8bio fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on In8bio Stock performance.
| Return On Equity | -1.75 | ||||
| Return On Asset | -0.73 | ||||
| Current Valuation | (142.01 K) | ||||
| Shares Outstanding | 3.44 M | ||||
| Price To Book | 0.54 X | ||||
| EBITDA | (27.78 M) | ||||
| Net Income | (30.44 M) | ||||
| Cash And Equivalents | 25.74 M | ||||
| Cash Per Share | 1.37 X | ||||
| Total Debt | 5.03 M | ||||
| Debt To Equity | 0.07 % | ||||
| Current Ratio | 9.08 X | ||||
| Book Value Per Share | 5.12 X | ||||
| Cash Flow From Operations | (24.15 M) | ||||
| Earnings Per Share | (13.20) X | ||||
| Market Capitalization | 7.47 M | ||||
| Total Asset | 20.94 M | ||||
| Retained Earnings | (121.66 M) | ||||
| Working Capital | 9.49 M | ||||
About In8bio Performance
By analyzing In8bio's fundamental ratios, stakeholders can gain valuable insights into In8bio's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if In8bio has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if In8bio has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 51.33 | 45.62 | |
| Return On Tangible Assets | (1.45) | (1.53) | |
| Return On Capital Employed | (1.70) | (1.79) | |
| Return On Assets | (1.45) | (1.53) | |
| Return On Equity | (2.10) | (2.00) |
Things to note about In8bio Inc performance evaluation
Checking the ongoing alerts about In8bio for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for In8bio Inc help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| In8bio Inc generated a negative expected return over the last 90 days | |
| In8bio Inc has high historical volatility and very poor performance | |
| In8bio Inc has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (30.44 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| In8bio Inc currently holds about 25.74 M in cash with (24.15 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.37. | |
| In8bio Inc has a poor financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: IN8bio regains compliance with Nasdaq minimum bid price requirement - Investing.com |
- Analyzing In8bio's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether In8bio's stock is overvalued or undervalued compared to its peers.
- Examining In8bio's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating In8bio's management team can have a significant impact on its success or failure. Reviewing the track record and experience of In8bio's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of In8bio's stock. These opinions can provide insight into In8bio's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for In8bio Stock analysis
When running In8bio's price analysis, check to measure In8bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy In8bio is operating at the current time. Most of In8bio's value examination focuses on studying past and present price action to predict the probability of In8bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move In8bio's price. Additionally, you may evaluate how the addition of In8bio to your portfolios can decrease your overall portfolio volatility.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Commodity Directory Find actively traded commodities issued by global exchanges |